Tokyo Tape
Sign in
← Torii Pharmaceutical

Annual report

4551.TEDINET S100T4CW
Period2023-01-01 → 2023-12-31
Filed2024-03-27
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 89
MetricValuePeriodScopeSource row
Revenue¥54.6bn2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥48.9bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥47.0bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥41.7bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥43.0bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Operating income¥5.0bn2023-01-01 → 2023-12-31StandaloneOperating income
Operating income¥5.5bn2022-01-01 → 2022-12-31StandaloneOperating income
Ordinary income¥5.3bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income¥5.5bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income¥4.8bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥5.0bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.7bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥5.6bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Profit before tax¥5.7bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Net income¥4.1bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income¥3.9bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income¥3.4bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income¥3.5bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income¥27.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Total assets¥133.4bnat 2023-12-31StandaloneAssets
Total assets¥133.7bnat 2022-12-31StandaloneAssets
Total assets¥130.8bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥126.0bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥139.9bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥13.3bnat 2023-12-31StandaloneLiabilities
Total liabilities¥14.5bnat 2022-12-31StandaloneLiabilities
Net assets / equity¥120.1bnat 2023-12-31StandaloneNet assets
Net assets / equity¥119.2bnat 2022-12-31StandaloneNet assets
Net assets / equity¥117.0bnat 2021-12-31dStandaloneNet assets
Net assets / equity¥115.1bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥113.1bnat 2019-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥5.0bnat 2023-12-31StandaloneCash and deposits
Cash and deposits¥9.2bnat 2022-12-31StandaloneCash and deposits
Cash & equivalents¥34.7bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥45.4bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥58.4bnat 2021-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥61.6bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥58.8bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥3.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥2.4bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥156m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥3.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥42.5bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥3.8bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥13.7bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥7.6bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥2.1bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3.8bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.7bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥146.62023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥140.392022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥120.132021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥124.472020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥974.982019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥124.462020-01-01 → 2020-12-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥1202023-01-01 → 2023-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1002022-01-01 → 2022-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥482021-01-01 → 2021-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥482020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥482019-01-01 → 2019-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥4,274.45at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,243.08at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,165.38at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥4,097.55at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥4,029.3at 2019-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio90.0%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.5%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio91.3%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio80.8%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE3.4%2023-01-01 → 2023-12-31StandaloneRate of return on equity (5-year summary)
ROE3.3%2022-01-01 → 2022-12-31StandaloneRate of return on equity (5-year summary)
ROE2.9%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
ROE3.1%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
ROE27.3%2019-01-01 → 2019-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued28,800,000at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees583at 2023-12-31StandaloneNumber of employees
Employees563at 2022-12-31StandaloneNumber of employees
Employees560at 2021-12-31dStandaloneNumber of employees
Employees568at 2020-12-31dStandaloneNumber of employees
Employees660at 2019-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 1
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2023-12-31583 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 949
ItemContextValueUnit
Address major shareholdersCurrentYearInstant_No2MajorShareholdersMember
Original text (Japanese)東京都港区浜松町二丁目11番３号
Name major shareholdersCurrentYearInstant_No3MajorShareholdersMember
Original text (Japanese)立花証券株式会社
Address major shareholdersCurrentYearInstant_No3MajorShareholdersMember
Original text (Japanese)東京都中央区日本橋茅場町一丁目13番14号
Name major shareholdersCurrentYearInstant_No4MajorShareholdersMember
Original text (Japanese)株式会社日本カストディ銀行（信託口）
Address major shareholdersCurrentYearInstant_No4MajorShareholdersMember
Original text (Japanese)東京都中央区晴海一丁目８番12号
Name major shareholdersCurrentYearInstant_No5MajorShareholdersMemberText · Plus
Address major shareholdersCurrentYearInstant_No5MajorShareholdersMemberText · Plus
Name major shareholdersCurrentYearInstant_No6MajorShareholdersMemberText · Plus
Address major shareholdersCurrentYearInstant_No6MajorShareholdersMemberText · Plus
Name major shareholdersCurrentYearInstant_No7MajorShareholdersMember
Original text (Japanese)鳥居薬品従業員持株会
Address major shareholdersCurrentYearInstant_No7MajorShareholdersMember
Original text (Japanese)東京都中央区日本橋本町三丁目４番１号
Name major shareholdersCurrentYearInstant_No8MajorShareholdersMember
Original text (Japanese)GOLDMAN SACHS INTERNATIONAL（常任代理人　ゴールドマン・サックス証券株式会社）
Address major shareholdersCurrentYearInstant_No8MajorShareholdersMemberText · Plus
Name major shareholdersCurrentYearInstant_No9MajorShareholdersMember
Original text (Japanese)野村證券株式会社
Address major shareholdersCurrentYearInstant_No9MajorShareholdersMember
Original text (Japanese)東京都中央区日本橋一丁目13番１号
Name major shareholdersCurrentYearInstant_No10MajorShareholdersMember
Original text (Japanese)MLI FOR SEGREGATED PB CLIENT（常任代理人　BOFA証券株式会社）
Address major shareholdersCurrentYearInstant_No10MajorShareholdersMemberText · Plus
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentYearInstant_SharesWithNoVotingRightsMember－
Description issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Description issued shares voting rightsCurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember－
Description issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember－
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentYearInstant_Row1Member
Original text (Japanese)鳥居薬品株式会社
Address of shareholder treasury shares etcCurrentYearInstant_Row1Member
Original text (Japanese)東京都中央区日本橋本町三丁目４番１号
Classes of shares etc (text)FilingDateInstantText · Plus
Acquisitions by resolution of shareholders meeting (text)FilingDateInstantText · Plus
Acquisitions by resolution of board of directors meeting (text)FilingDateInstantText · Plus
Acquisitions not based on resolution of shareholders meeting or board of directors meeting (text)FilingDateInstantText · Plus
Disposals or holding of acquired treasury shares (text)FilingDateInstantText · Plus
Dividend policy (text)FilingDateInstantText · Plus
Date of resolution dividends of surplusFilingDateInstant_Row1Member2023-07-31
Resolution dividends of surplusFilingDateInstant_Row1Member
Original text (Japanese)取締役会決議
Date of resolution dividends of surplusFilingDateInstant_Row2Member2024-03-27
Resolution dividends of surplusFilingDateInstant_Row2Member
Original text (Japanese)定時株主総会決議
Overview of corporate governance (text)FilingDateInstantText · Plus
Corporate governance company with audit and supervisory committee (text)FilingDateInstantText · Plus
Information about officers (text)FilingDateInstantText · Plus
Official title or position information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000MatsudaGoichiMember
Original text (Japanese)代表取締役社長
Name information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000MatsudaGoichiMember
Original text (Japanese)松　田　剛　一
Date of birth information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000MatsudaGoichiMember1967-02-13
Career summary information about directors and corporate auditors (text)FilingDateInstant_jpcrp030000-asr_E00934-000MatsudaGoichiMemberText · Plus
Term of office information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000MatsudaGoichiMember
Original text (Japanese)（注）４
Official title or position information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000KondoNobumasaMember
Original text (Japanese)代表取締役 副社長
Name information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000KondoNobumasaMember
Original text (Japanese)近　藤　紳　雅
Date of birth information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000KondoNobumasaMember1968-09-28
Career summary information about directors and corporate auditors (text)FilingDateInstant_jpcrp030000-asr_E00934-000KondoNobumasaMemberText · Plus
Term of office information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00934-000KondoNobumasaMember
Original text (Japanese)（注）４

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2022-12-31pass rounding
balance sheet identitynon_consolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass